Edition:
India

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

15.04USD
17 Nov 2017
Change (% chg)

-- (--)
Prev Close
$15.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
122,095
52-wk High
$21.35
52-wk Low
$4.74

Chart for

About

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both... (more)

Overall

Beta: 0.51
Market Cap(Mil.): $274.23
Shares Outstanding(Mil.): 25.63
Dividend: --
Yield (%): --

Financials

BRIEF-Uniqure Q3 loss per share $0.40

* Uniqure announces third quarter 2017 financial results and recent company progress

01 Nov 2017

BRIEF-UniQure reports Q3 loss $0.40/shr

* UniQure announces third quarter 2017 financial results and recent company progress

01 Nov 2017

BRIEF-Uniqure announces proposed public offering

* Uniqure NV - ‍ commenced an underwritten public offering of 5 million of its ordinary shares Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-uniQure acquires patent family providing broad protection of hyperactive padua variant of factor IX

* uniQure strengthens intellectual property portfolio with acquisition of patent family providing broad protection of the hyperactive padua variant of factor ix (FIX-padua) Source text for Eikon: Further company coverage:

19 Oct 2017

BRIEF-Uniqure announces AMT-061 to enter pivotal study in 2018

* Uniqure announces Hemophilia B gene therapy program to enter pivotal study with FIX-Padua variant in 2018

19 Oct 2017

BRIEF-Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease

* Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease Source text for Eikon: Further company coverage:

06 Oct 2017

BRIEF-Uniqure NV Q2 revenue $4.9 million

* Uniqure announces second quarter 2017 financial results and recent company progress

08 Aug 2017

BRIEF-Uniqure NV - ‍Scott Mcmillan named chief operating officer

* Uniqure announces leadership team appointments and nominations to its board of directors

07 Aug 2017

BRIEF-Uniqure reacquires development and commercialization rights for gene therapy candidate in Hemophilia B

* Uniqure reacquires development and commercialization rights for its gene therapy candidate in Hemophilia B

31 Jul 2017

BRIEF-uniQure reacquires development and commercialization rights for its gene therapy candidate in hemophilia B

* uniQure reacquires development and commercialization rights for its gene therapy candidate in hemophilia B

31 Jul 2017

Competitors

Earnings vs. Estimates